A Risk-Based Auditing Process for Pharmaceutical Manufacturers

References

1. 1.↵
   International Conference on Harmonization. ICH Q9. Guideline on Quality Risk Management, November 2005.

   Google Scholar
2. 2.↵
   1. Rönninger S.,
   2. Schmitt S.,
   3. Rangavajhula V.,
   4. Lyda J.,
   5. Hough E.

   Considerations on auditing and GxP requirements along the product life cycle. PDA J. Pharm. Sci. Technol. 2012, 66(5), 396–402.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
3. 3.↵
   PDA Technical Report No. 54 (TR 54) Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations, 2012.

   Google Scholar
4. 4.↵
   1. Rönninger S.,
   2. Holmes M.

   A risk-based approach for scheduling audits. PDA J. Pharm. Sci. Technol. 2009, 63(6), 575–588.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
5. 5.↵
   PIC/S. A Recommended Model for Risk Based Inspection Planning in the GMP Environment. PI 037-1, January 1, 2012.

   Google Scholar
6. 6.↵
   Health Canada. Health Products and Food Branch, Risk Classification of Post-Market Reporting Compliance Observations, Guide-0063, November 21, 2005.

   Google Scholar
7. 7.↵
   European Medicines Agency. Compilation of Community Procedures on Inspections and Exchange of Information, EMA/INS/GMP/321252/2012/Rev. 15, July 16, 2012.

   Google Scholar
8. 8.↵
   1. Rönninger S.,
   2. Berberich J.,
   3. Fischer G.,
   4. Persson I.,
   5. Wandt C.,
   6. Wall L.

   How can we balance value, effort and risk in foreign GMP inspections? A future perspective. GMP Review, 2012, 10, 14–18.

   OpenUrlGoogle Scholar